Bernard Schachtel and Charleston Laboratories - Free people check

(1 - 13 from 20

)

Charleston Laboratories, Inc. Phase I Clinical Trial - News -...

www.charlestondigitalcorridor.com

... in the lab, resulting in the optimal formulation of this drug, it is ready for testing in man," said Dr. Bernard Schachtel, Chief Medical Officer at...

Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Phase...

www.prnewswire.com

... while preventing opioid-induced nausea and vomiting," said Bernard Schachtel, M.D., Chief Scientific Officer at Charleston Laboratories, Inc.

Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3...

www.prnewswire.com

... Charleston Labs and for patients with acute moderate to severe pain," said Dr. Bernard Schachtel, Chief Scientific Officer of Charleston Labs.

patentbuddy: Bernard Schachtel

CHARLESTON LABORATORIES, INC., Jupiter, FL, US

Charleston Laboratories, Inc. Appoints Bernard Schachtel, M.D. ...www.docdatabase.net › more-charleston-laboratories-inc-appoints-bernard-...

www.docdatabase.net

Jul 31, · NEWS Charleston Laboratories, Inc. Appoints Bernard Schachtel, M.D. Chief Medical Officer World Reno This file you can free ...

Charleston Laboratories, Inc. Appoints Bernard Schachtel, M.D. Chief...

charlestonlabs.com

Charleston Laboratories, Inc. Appoints Bernard Schachtel, ... Schachtel is the President and Medical Director of Schachtel Research Company (SRC), ...

A Controlled Study to Determine the Efficacy and Safety of CL

clinicaltrials.gov

Study Director: Bernard Schachtel, MD, Charleston Laboratories, Inc. More Information. Go to sections. Top of Page Study Description Study Design Arms and ...

Charleston Laboratories, Inc. And Daiichi Sankyo Announce Completion...

www.biospace.com

Charleston Laboratories, Inc. And Daiichi Sankyo Announce Completion Of A Pharmacokinetics Study On CL read this article along with other careers...

Charleston Laboratories, Inc. Announces Completion Of A Second Phase...

www.biospace.com

Charleston Laboratories, Inc. Announces Completion Of A Second Phase 3 Clinical Trial On Its Lead Product, CL-108, And The Appointment Of Dr. Raymond Dionne To...

Charleston Laboratories & Daiichi Sankyo Announce Completion of...

drug-dev.com

Charleston Laboratories, Inc. and its co-development and co-commercialization partner, Daiichi Sankyo, Inc., recently announced the completion of a

Charleston Laboratories, Inc. And Daiichi Sankyo, Inc. Initiate Two ...www.biospace.com › article › releases › charleston-laboratories-inc-and-dai...

www.biospace.com

Nov 20, · "As a result of the planning and hard work by our Chief Scientific Officer, Dr. Bernard Schachtel, and his dedicated research staff, Charleston is ...